Stocklytics Platform
Asset logo for symbol BMRN
BioMarin Pharmaceutical
BMRN76
$84.59arrow_drop_down1.16%-$1.00
Asset logo for symbol BMRN
BMRN76

$84.59

arrow_drop_down1.16%

Performance History

Chart placeholder
Key Stats
Open$85.71
Prev. Close$85.59
EPS1.06
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range84.41
86.45
52 Week Range73.68
99.56
Ratios
EPS1.06

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$738.87B
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$382.01B
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical Inc. (BMRN) is a globally recognized biotechnology company focused on developing and commercializing innovative therapies for patients with serious and life-threatening rare genetic diseases. With a mission to provide hope to patients and their families, BioMarin is dedicated to advancing medicine in areas where few, if any, options exist. Through its cutting-edge research and development efforts, the company has made significant strides in addressing unmet medical needs and improving the quality of life for patients around the world.
BioMarin's extensive portfolio of products includes treatments for rare genetic disorders such as phenylketonuria (PKU), mucopolysaccharidosis type I (MPS I), and Batten disease. These conditions, while rare, can have devastating effects on individuals and their families. BioMarin's therapies offer hope for patients by addressing the underlying cause of these diseases and providing targeted treatment options.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jean-Jacques Bienaime M.B.A., MBA
Headquarters
San Rafael
Employees
3082
Exchange
NASDAQ
add BioMarin Pharmaceutical  to watchlist

Keep an eye on BioMarin Pharmaceutical

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is BioMarin Pharmaceutical 's (BMRN) price per share?
The current price per share for BioMarin Pharmaceutical (BMRN) is $84.59. The stock has seen a price change of -$1 recently, indicating a -1.17% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for BioMarin Pharmaceutical (BMRN)?
For BioMarin Pharmaceutical (BMRN), the 52-week high is $99.56, which is 17.7% from the current price. The 52-week low is $73.68, the current price is 14.81% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is BioMarin Pharmaceutical (BMRN) a growth stock?
BioMarin Pharmaceutical (BMRN) has shown an average price growth of 0.41% over the past three years. It has received a score of 63 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying BioMarin Pharmaceutical as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is BioMarin Pharmaceutical (BMRN) stock price performance year to date (YTD)?
As of the latest data, BioMarin Pharmaceutical (BMRN) has a year-to-date price change of -13.73%. Over the past month, the stock has experienced a price change of -0.45%. Over the last three months, the change has been 2.95%. Over the past six months, the figure is -7.3%. Looking at a longer horizon, the five-year price change stands at 4.86%.
help
Is BioMarin Pharmaceutical (BMRN) a profitable company?
BioMarin Pharmaceutical (BMRN) has a net income of $167.64M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 76.15% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 12.09% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.42B, with a revenue growth rate of 15.42%, providing insight into the company's sales performance and growth. The gross profit is $1.84B. Operating income is noted at $157.6M. Furthermore, the EBITDA is $349.25M.
help
What is the market capitalization of BioMarin Pharmaceutical (BMRN)?
BioMarin Pharmaceutical (BMRN) has a market capitalization of $16.06B. The average daily trading volume is 1.33M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level